Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression

Oncogene

Volumn 33, Issue 17, 2014, Pages 2215-2224

  Sato, T ^a   Tran, T H ^a   Peck, A R ^a   Girondo, M A ^a   Liu, C ^a   Goodman, C R ^a   Neilson, L M ^a   Freydin, B ^b   Chervoneva, I ^b   Hyslop, T ^b   Kovatich, A J ^c   Hooke, J A ^d   Shriver, C D ^d   Fuchs, S Y ^e   Rui, H ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c MDR Global Systems LLC   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

BCL6; breast cancer; CK5; progesterone; prolactin; Stat5

Indexed keywords

CYTOKERATIN 5; ESTRADIOL; GESTAGEN; MESSENGER RNA; PROGESTERONE; PROLACTIN; PROLACTIN RECEPTOR; PROMEGESTONE; PROTEIN BCL 6; STAT5 PROTEIN;

ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; FEMALE; HORMONE ACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LYMPHOMA; ONCOGENE; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KERATIN-5; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, HORMONE-DEPENDENT; PREMENOPAUSE; PROGESTERONE; PROGESTERONE CONGENERS; PROLACTIN; PROMEGESTONE; RECEPTORS, ESTROGEN; STAT5 TRANSCRIPTION FACTOR;

EID: 84899629949     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.172     Document Type: Article

References (47)

1. Keen JC, Davidson NE. The biology of breast carcinoma. Cancer 2003; 97(3 Suppl): 825-833.
2. Lim E, Metzger-Filho O, Winer EP. The natural history of hormone receptorpositive breast cancer. Oncology (Williston Park) 2012; 26: 688-694, 696.
3. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
4. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-284.
5. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008; 10: R25.
6. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100: 672-679.
7. Sartorius CA, Harvell DM, Shen T, Horwitz KB. Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth. Cancer Res 2005; 65: 9779-9788.
8. Horwitz KB, Dye WW, Harrell JC, Kabos P, Sartorius CA. Rare steroid receptornegative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci USA 2008; 105: 5774-5779.
9. Kabos P, Haughian JM, Wang X, Dye WW, Finlayson C, Elias A et al. Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers. Breast Cancer Res Treat 2011; 128: 45-55.
10. Haughian JM, Pinto MP, Harrell JC, Bliesner BS, Joensuu KM, Dye WW et al. Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. Proc Natl Acad Sci USA 2011; 109: 2742-2747.
11. Lee HJ, Ormandy CJ. Interplay between progesterone and prolactin in mammary development and implications for breast cancer. Mol Cell Endocrinol 2012; 357: 101-107.
12. Gouilleux F, Wakao H, Mundt M, Groner B. Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. EMBO J 1994; 13: 4361-4369.
13. Liu X, Robinson GW, Gouilleux F, Groner B, Hennighausen L. Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc Natl Acad Sci USA 1995; 92: 8831-8835.
14. Peck AR, Witkiewicz AK, Liu C, Stringer GA, Klimowicz AC, Pequignot E et al. Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol 2011; 29: 2448-2458.
15. Yamashita H, Nishio M, Ando Y, Zhang Z, Hamaguchi M, Mita K et al. Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer. Endocr Relat Cancer 2006; 13: 885-893.
16. Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, Kononen J et al. Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol 2004; 22: 2053-2060.
17. Cotarla I, Ren S, Zhang Y, Gehan E, Singh B, Furth PA. Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer 2004; 108: 665-671.
18. Peck AR, Witkiewicz AK, Liu C, Klimowicz AC, Stringer GA, Pequignot E et al. Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes. Breast Cancer Res 2012; 14: R130.
19. Sultan AS, Xie J, LeBaron MJ, Ealley EL, Nevalainen MT, Rui H. Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene 2005; 24: 746-760.
20. Nouhi Z, Chughtai N, Hartley S, Cocolakis E, Lebrun JJ, Ali S. Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. Cancer Res 2006; 66: 1824-1832.
21. Sultan AS, Brim H, Sherif ZA. Co-overexpression of Janus kinase 2 and signal transducer and activator of transcription 5a promotes differentiation of mammary cancer cells through reversal of epithelial-mesenchymal transition. Cancer Sci 2008; 99: 272-279.
22. Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S et al. BCL6 enables Ph acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature 2011; 473: 384-388.
23. Tran TH, Utama FE, Lin J, Yang N, Sjolund AB, Ryder A et al. Prolactin inhibits BCL6 expression in breast cancer through a Stat5a-dependent mechanism. Cancer Res 2010; 70: 1711-1721.
24. Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 2002; 277: 5209-5218.
25. Walker SR, Nelson EA, Zou L, Chaudhury M, Signoretti S, Richardson A et al. Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res 2009; 7: 966-976.
26. Neilson LM, Zhu J, Xie J, Malabarba MG, Sakamoto K, Wagner KU et al. Coactivation of Jak1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and Stat3 and enhancement of Akt and Stat5a/b Pathways. Mol Endocrinol 2007; 21: 2218-2232.
27. Knutson TP, Daniel AR, Fan D, Silverstein KA, Covington KR, Fuqua SA et al. Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression. Breast Cancer Res 2012; 14: R95.
28. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. Jama 2002; 288: 321-333.
29. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-427.
30. Horwitz KB, Sartorius CA. Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. J Clin Endocrinol Metab 2008; 93: 3295-3298.
31. Aldaz CM, Liao QY, LaBate M, Johnston DA. Medroxyprogesterone acetate accelerates the development and increases the incidence of mouse mammary tumors induced by dimethylbenzanthracene. Carcinogenesis 1996; 17: 2069-2072.
32. Liu R, Zhou Z, Zhao D, Chen C. The induction of KLF5 transcription factor by progesterone contributes to progesterone-induced breast cancer cell proliferation and dedifferentiation. Mol Endocrinol 2011; 25: 1137-1144.
33. Tunyaplin C, Shaffer AL, Angelin-Duclos CD, Yu X, Staudt LM, Calame KL. Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J Immunol 2004; 173: 1158-1165.
34. Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 2000; 13: 199-212.
35. Cattoretti G, Pasqualucci L, Ballon G, Tam W, Nandula SV, Shen Q et al. Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell 2005; 7: 445-455.
36. Cerchietti LC, Yang SN, Shaknovich R, Hatzi K, Polo JM, Chadburn A et al. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood 2009; 113: 3397-3405.
37. Cerchietti LC, Ghetu AF, Zhu X, Da Silva GF, Zhong S, Matthews M et al. A smallmolecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell 2010; 17: 400-411.
38. Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim YM et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med 2011; 208: 2163-2174.
39. Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 2012; 21: 430-446.
40. Logarajah S, Hunter P, Kraman M, Steele D, Lakhani S, Bobrow L et al. BCL-6 is expressed in breast cancer and prevents mammary epithelial differentiation. Oncogene 2003; 22: 5572-5578.
41. Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL et al. Progesterone induces adult mammary stem cell expansion. Nature 2010; 465: 803-807.
42. Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER et al. Control of mammary stem cell function by steroid hormone signalling. Nature 2010; 465: 798-802.
43. Pierson-Mullany LK, Lange CA. Phosphorylation of progesterone receptor serine 400 mediates ligand-independent transcriptional activity in response to activation of cyclin-dependent protein kinase 2. Mol Cell Biol 2004; 24: 10542-10557.
44. Jacobsen BM, Schittone SA, Richer JK, Horwitz KB. Progesterone- independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology. Mol Endocrinol 2005; 19: 574-587.
45. Daniel AR, Lange CA. Protein kinases mediate ligand-independent derepression of sumoylated progesterone receptors in breast cancer cells. Proc Natl Acad Sci USA 2009; 106: 14287-14292.
46. Dagvadorj A, Kirken RA, Leiby B, Karras J, Nevalainen MT. Transcription factor signal transducer and activator of transcription 5 promotes growth of human prostate cancer cells in vivo. Clin Cancer Res 2008; 14: 1317-1324.
47. Johnson KJ, Peck AR, Liu C, Tran TH, Utama FE, Sjolund AB et al. PTP1B suppresses prolactin activation of Stat5 in breast cancer cells. Am J Pathol 2010; 177: 2971-2983.